Bearish
Pfizer's stock remains below key moving averages amid ongoing challenges.
Pfizer's stock continues to trade below its 50-day and 200-day simple moving averages, reflecting investor caution regarding the company's growth prospects. The stock closed at $25.05 on July 17, 2026, with an intraday high of $25.64 and a low of $24.975. Analysts have expressed concerns over declining COVID-related revenues and patent expirations, which may impact future earnings. Additionally, HSBC downgraded Pfizer's rating to 'Hold' due to a lack of near-term catalysts.
Key points
- Pfizer's stock trading below key moving averages indicates investor caution.
- Declining COVID-related revenues and patent expirations may impact future earnings.
- HSBC downgraded Pfizer's rating to 'Hold' due to a lack of near-term catalysts.
Sources
AI-generated from public news sources. Not financial advice.
